




Supplementary Materials



**Figure S1.** Overexpression of the MCPIP1-D141N mutant did not cause cleavage of MCPIP1 in TNF- $\alpha$ -treated cells. T-REx-293 cells with the HA-MCPIP1-D141N mutant (HA-D141N) were pretreated without or with 1  $\mu$ g/ml of doxycycline (Dox) for 16 h, and then treated with or without 10 ng/ml TNF- $\alpha$  for 1 and 2 h. Total cell lysates were collected, and protein expressions were determined by Western blotting.



**Figure S2.** A proteasome inhibitor did not suppress MCPIP1 cleavage in TNF- $\alpha$ -treated cells. T-REx-293 cells with wild-type hemagglutinin (HA)-MCPIP1 (HA-MCPIP1) were pretreated without or with 1  $\mu$ g/ml of doxycycline (Dox) for 16 h, and then treated with or without 10 ng/ml TNF- $\alpha$  for 2 h. Total cell lysates were collected, and protein expressions were determined by Western blotting.



**Figure S3.** Overexpression of MCPIP1 inhibited NF- $\kappa$ B binding activity in TNF- $\alpha$ -treated cells. T-REx-293 cells with wild-type hemagglutinin (HA)-MCPIP1 or the HA-MCPIP1-D141N mutant (HA-D141N) were pretreated without or with 1  $\mu$ g/ml of doxycycline (Dox) for 16 h, and then treated without or with 10 ng/ml TNF- $\alpha$  for 30~60 min. Nuclear extracts were prepared, and an electrophoretic mobility shift assay (EMSA) was carried out as described in "Methods and Materials". The specificity of NF- $\kappa$ B complex formation is shown.